Complementary Activity of ETV5, RBPJ, and TCF3 Drives Formative Transition from Naive Pluripotency

被引:70
作者
Kalkan, Tuzer [1 ]
Bornelov, Susanne [1 ,4 ]
Mulas, Carla [1 ,4 ]
Diamanti, Evangelia [1 ]
Lohoff, Tim [1 ,2 ]
Ralser, Meryem [1 ]
Middelkamp, Sjors [1 ,3 ]
Lombard, Patrick [1 ]
Nichols, Jennifer [1 ,2 ]
Smith, Austin [1 ,3 ]
机构
[1] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge CB2 1QR, England
[2] Univ Cambridge, Dept Physiol Dev & Neurosci, Downing St, Cambridge CB2 3DY, England
[3] Radboud Univ Nijmegen, Fac Sci, Dept Mol Biol, NL-6525 GA Nijmegen, Netherlands
[4] Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1GA, England
基金
英国生物技术与生命科学研究理事会; 英国惠康基金;
关键词
EMBRYONIC STEM-CELLS; SELF-RENEWAL; TRANSCRIPTION FACTORS; GROUND-STATE; DIFFERENTIATION; NOTCH; ACTIVATION; PROTEINS; PEA3; ERM;
D O I
10.1016/j.stem.2019.03.017
中图分类号
Q813 [细胞工程];
学科分类号
摘要
The gene regulatory network (GRN) of naive mouse embryonic stem cells (ESCs) must be reconfigured to enable lineage commitment. TCF3 sanctions rewiring by suppressing components of the ESC transcription factor circuitry. However, TCF3 depletion only delays and does not prevent transition to formative pluripotency. Here, we delineate additional contributions of the ETS-family transcription factor ETV5 and the repressor RBPJ. In response to ERK signaling, ETV5 switches activity from supporting self-renewal and undergoes genome relocation linked to commissioning of enhancers activated in formative epiblast. Independent upregulation of RBPJ prevents re-expression of potent naive factors, TBX3 and NANOG, to secure exit from the naive state. Triple deletion of Etv5, Rbpj, and Tcf3 disables ESCs, such that they remain largely undifferentiated and locked in self-renewal, even in the presence of differentiation stimuli. Thus, genetic elimination of three complementary drivers of network transition stalls developmental progression, emulating environmental insulation by small-molecule inhibitors.
引用
收藏
页码:785 / +
页数:24
相关论文
共 82 条
[21]   Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu [J].
Goel, A ;
Janknecht, R .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (17) :6243-6254
[22]   Dynamic modification of the ETS transcription factor PEA3 by sumoylation and p300-mediated acetylation [J].
Guo, Baoqiang ;
Panagiotaki, Niki ;
Warwood, Stacey ;
Sharrocks, Andrew D. .
NUCLEIC ACIDS RESEARCH, 2011, 39 (15) :6403-6413
[23]   A PiggyBac-Based Recessive Screening Method to Identify Pluripotency Regulators [J].
Guo, Ge ;
Huang, Yue ;
Humphreys, Peter ;
Wang, Xiaozhong ;
Smith, Austin .
PLOS ONE, 2011, 6 (04)
[24]   Klf4 reverts developmentally programmed restriction of ground state pluripotency [J].
Guo, Ge ;
Yang, Jian ;
Nichols, Jennifer ;
Hall, John Simon ;
Eyres, Isobel ;
Mansfield, William ;
Smith, Austin .
DEVELOPMENT, 2009, 136 (07) :1063-1069
[25]   Reconstitution of the Mouse Germ Cell Specification Pathway in Culture by Pluripotent Stem Cells [J].
Hayashi, Katsuhiko ;
Ohta, Hiroshi ;
Kurimoto, Kazuki ;
Aramaki, Shinya ;
Saitou, Mitinori .
CELL, 2011, 146 (04) :519-532
[26]   Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family [J].
Hollenhorst, Peter C. ;
Shah, Atul A. ;
Hopkins, Christopher ;
Graves, Barbara J. .
GENES & DEVELOPMENT, 2007, 21 (15) :1882-1894
[27]   Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells [J].
Hollenhorst, Peter C. ;
Ferris, Mary W. ;
Hull, Megan A. ;
Chae, Heejoon ;
Kim, Sun ;
Graves, Barbara J. .
GENES & DEVELOPMENT, 2011, 25 (20) :2147-2157
[28]   Genomic and Biochemical Insights into the Specificity of ETS Transcription Factors [J].
Hollenhorst, Peter C. ;
McIntosh, Lawrence P. ;
Graves, Barbara J. .
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 80, 2011, 80 :437-471
[29]   Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes [J].
Ingolia, Nicholas T. ;
Lareau, Liana F. ;
Weissman, Jonathan S. .
CELL, 2011, 147 (04) :789-802
[30]  
Janknecht R, 1996, ONCOGENE, V13, P1745